

General

Title

Bladder cancer: proportion of patients with bladder cancer who undergo transurethral resection of bladder tumour (TURBT) where it is documented whether the resection was complete or not at initial resection.

Source(s)

NHS Scotland, Scottish Cancer Taskforce, National Cancer Quality Steering Group. Bladder cancer clinical quality performance indicators. Edinburgh (Scotland): Healthcare Improvement Scotland; 2016 Jun. 38 p. [19 references]

Measure Domain

Primary Measure Domain

Clinical Quality Measures: Process

Secondary Measure Domain

Does not apply to this measure

Brief Abstract

Description

This measure is used to assess the proportion of patients with bladder cancer who undergo transurethral resection of bladder tumour (TURBT) where it is documented whether the resection was complete or not at initial resection.

This Cancer Quality Performance Indicator (QPI) measure is separated into three parts. Please refer to the following related NQMC summaries:

Bladder cancer: proportion of patients with bladder cancer who undergo transurethral resection of bladder tumour (TURBT) where a bladder diagram/detailed description with documentation of tumour location, size, number and appearance has been used at initial resection.

Bladder cancer: proportion of patients with bladder cancer who undergo transurethral resection of bladder tumour (TURBT) where detrusor muscle is included in the specimen at initial resection.

Note from the National Quality Measures Clearinghouse: This measure is part of the QPIs collection. For more information, including a complete list of QPI measure sets, please visit the [Healthcare Improvement Scotland Web site](#) .

Rationale

Transurethral resection of bladder tumour (TURBT) is considered to be the gold standard initial treatment of non muscle invasive bladder cancer (NMIBC), with the aim of completely removing all macroscopic tumours and obtaining tissue for essential pathological evaluation (Bladder Cancer Clinical Guideline Update Panel, 2007). Although the 10-year disease specific survival for Ta and T1 NMIBC is 85% and 70% (Lamm et al., 2008) respectively; the risk of recurrence is as high as 70% (Bladder Cancer Clinical Guideline Update Panel, 2007). Most recurrences are detected at the first check cystoscopy following initial TURBT and therefore attributable to residual disease or missed tumours at initial TURBT. These recurrences have been shown to vary according to the quality of the initial TURBT (Brausi et al., 2002). Several surgical factors have hence been found to be associated with a good quality TURBT, thereby have been shown to be a surrogate for quality of TURBT. These factors have been incorporated into this Cancer Quality Performance Indicator (QPI).

It is recommended that a TURBT is performed in a systematic manner, a complete resection with detrusor muscle in the sample is the ultimate aim (The Dutch Society for Urology, 2009). Adequate documentation (use of a bladder diagram) with a conclusion regarding radicality or residual tumour is recommended (Babjuk et al., 2011; The Dutch Society for Urology, 2009).

The procedure should be carried out by an experienced surgeon, and when carried out by a trainee this should be under supervision of an experienced operator.

Evidence for Rationale

Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhmle A, Palou-Redorta J, Rouprêt M, European Association of Urology (EAU). EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. *Eur Urol.* 2011 Jun;59(6):997-1008. [PubMed](#)

Bladder Cancer Clinical Guideline Update Panel. Guideline for the management of nonmuscle invasive bladder cancer: (stages Ta, T1, and Tis): 2007 update. Linthicum (MD): American Urological Association Education and Research, Inc; 2007. 133 p. [31 references]

Brausi M, Collette L, Kurth K, van der Meijden AP, Oosterlinck W, Witjes JA, Newling D, Bouffieux C, Sylvester RJ, EORTC Genito-Urinary Tract Cancer Collaborative Group. Variability in the recurrence rate at the first follow up cystoscopy after TUR in stage TaT1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. *Eur Urol.* 2002 May;41(5):523-31. [PubMed](#)

Lamm D, Colombel M, Persad R, Soloway M, Bohle A, Palou J, Witjes JA, Akaza H, Buckley R, Brausi M. Clinical practice recommendations for the management of non-muscle invasive bladder cancer. *Eur Urol Suppl.* 2008;7(2008):651-66. [72 references]

NHS Scotland, Scottish Cancer Taskforce, National Cancer Quality Steering Group. Bladder cancer clinical quality performance indicators. Edinburgh (Scotland): Healthcare Improvement Scotland; 2016 Jun. 38 p. [19 references]

The Dutch Society for Urology. Bladder carcinoma. Utrecht (The Netherlands): Comprehensive Cancer Centre the Netherlands; 2009 Feb 13. 128 p.

Primary Health Components

Bladder cancer; transurethral resection of bladder tumour (TURBT); complete resection

Denominator Description

All patients with bladder cancer who undergo transurethral resection of bladder tumour (TURBT) (see the related "Denominator Inclusions/Exclusions" field)

Numerator Description

Number of patients with bladder cancer who undergo transurethral resection of bladder tumour (TURBT) where it is documented whether the resection was complete or not at initial resection (see the related "Numerator Inclusions/Exclusions" field)

Evidence Supporting the Measure

Type of Evidence Supporting the Criterion of Quality for the Measure

A clinical practice guideline or other peer-reviewed synthesis of the clinical research evidence

A formal consensus procedure, involving experts in relevant clinical, methodological, public health and organizational sciences

One or more research studies published in a National Library of Medicine (NLM) indexed, peer-reviewed journal

Additional Information Supporting Need for the Measure

Unspecified

Extent of Measure Testing

The collection of data is piloted on a small number of patient records using a paper data collection form produced by the Information Services Division (ISD). The aim is to identify any anomalies or difficulties with data collection prior to full implementation. At least one NHS board in each Regional Cancer Network participates in the pilot.

Evidence for Extent of Measure Testing

NHS Scotland. National cancer quality performance indicators: overview of development process. Edinburgh (Scotland): NHS Scotland; 2012 Dec. 7 p.

State of Use of the Measure

State of Use

Current routine use

Current Use

not defined yet

Application of the Measure in its Current Use

Measurement Setting

Hospital Inpatient

Hospital Outpatient

Professionals Involved in Delivery of Health Services

not defined yet

Least Aggregated Level of Services Delivery Addressed

Single Health Care Delivery or Public Health Organizations

Statement of Acceptable Minimum Sample Size

Unspecified

Target Population Age

Unspecified

Target Population Gender

Either male or female

National Strategy for Quality Improvement in Health Care

National Quality Strategy Aim

Better Care

National Quality Strategy Priority

Prevention and Treatment of Leading Causes of Mortality

Institute of Medicine (IOM) National Health Care Quality Report Categories

IOM Care Need

Getting Better

IOM Domain

Effectiveness

Data Collection for the Measure

Case Finding Period

Unspecified

Denominator Sampling Frame

Patients associated with provider

Denominator (Index) Event or Characteristic

Clinical Condition

Therapeutic Intervention

Denominator Time Window

not defined yet

Denominator Inclusions/Exclusions

Inclusions

All patients with bladder cancer who undergo transurethral resection of bladder tumour (TURBT)

Exclusions

Patients undergoing palliative resection

Patients with very small tumours (less than or equal to 5 mm)

Exclusions/Exceptions

not defined yet

Numerator Inclusions/Exclusions

Inclusions

Number of patients with bladder cancer who undergo transurethral resection of bladder tumour (TURBT) where it is documented whether the resection was complete or not at initial resection

Exclusions

Patients undergoing palliative resection

Patients with very small tumours (less than or equal to 5 mm)

Numerator Search Strategy

Fixed time period or point in time

Data Source

Electronic health/medical record

Paper medical record

Type of Health State

Does not apply to this measure

Instruments Used and/or Associated with the Measure

Unspecified

Computation of the Measure

Measure Specifies Disaggregation

Does not apply to this measure

Scoring

Rate/Proportion

Interpretation of Score

Desired value is a higher score

Allowance for Patient or Population Factors

not defined yet

Standard of Comparison

not defined yet

Prescriptive Standard

Target: 80%

The tolerance within this target level accounts for the fact that it is not always possible to include detrusor muscle within the specimen.

Evidence for Prescriptive Standard

Identifying Information

Original Title

QPI 2 (ii) – quality of transurethral resection of bladder tumour recording.

Measure Collection Name

Cancer Quality Performance Indicators (QPIs)

Measure Set Name

Bladder Cancer

Submitter

NHS Scotland - National Government Agency [Non-U.S.]

Scottish Cancer Taskforce - National Government Agency [Non-U.S.]

Developer

NHS Scotland - National Government Agency [Non-U.S.]

Scottish Cancer Taskforce - National Government Agency [Non-U.S.]

Funding Source(s)

Scottish Government

Composition of the Group that Developed the Measure

Bladder Cancer QPI Development Group

Financial Disclosures/Other Potential Conflicts of Interest

Unspecified

Adaptation

This measure was not adapted from another source.

Date of Most Current Version in NQMC

2016 Jun

Measure Maintenance

The Cancer Quality Performance Indicators (QPIs) will be kept under regular review and be responsive to changes in clinical practice and emerging evidence.

Date of Next Anticipated Revision

2018 Feb

Measure Status

This is the current release of the measure.

Measure Availability

Source document available from the [Healthcare Improvement Scotland Web site](#) .

For more information, contact the Healthcare Improvement Scotland at Gyle Square, 1 South Gyle Crescent, Edinburgh, Scotland EH12 9EB; Phone: 0131 623 4300; E-mail: comments.his@nhs.net; Web site: www.healthcareimprovementscotland.org/ .

Companion Documents

The following is available:

NHS Scotland. National cancer quality performance indicators: overview of development process. Edinburgh (Scotland): NHS Scotland; 2012 Dec. 7 p. This document is available from the [Healthcare Improvement Scotland Web site](#) .

NQMC Status

This NQMC summary was completed by ECRI Institute on May 3, 2017. The information was verified by the measure developer on May 23, 2017.

Copyright Statement

No copyright restrictions apply.

Production

Source(s)

NHS Scotland, Scottish Cancer Taskforce, National Cancer Quality Steering Group. Bladder cancer clinical quality performance indicators. Edinburgh (Scotland): Healthcare Improvement Scotland; 2016 Jun. 38 p. [19 references]

Disclaimer

NQMC Disclaimer

The National Quality Measures Clearinghouse (NQMC) does not develop, produce, approve, or endorse the measures represented on this site.

All measures summarized by NQMC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public and private organizations, other government agencies, health care organizations or plans, individuals, and similar entities.

Measures represented on the NQMC Web site are submitted by measure developers, and are screened solely to determine that they meet the [NQMC Inclusion Criteria](#).

NQMC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or its reliability and/or validity of the quality measures and related materials represented on this site. Moreover, the views and opinions of developers or authors of measures represented on this site do not necessarily state or reflect those of NQMC, AHRQ, or its contractor, ECRI Institute, and inclusion or hosting of measures in NQMC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding measure content are directed to contact the measure developer.